Hartman Institute for Therapeutic Organ Regeneration

Use of Integra and interval brachytherapy in a 2-stage auricular reconstruction after excision of a recurrent keloid.

TitleUse of Integra and interval brachytherapy in a 2-stage auricular reconstruction after excision of a recurrent keloid.
Publication TypeJournal Article
Year of Publication2012
AuthorsReiffel AJ, Sohn AM, Henderson PW, Fullerton N, Spector JA
JournalJ Craniofac Surg
Volume23
Issue5
Paginatione379-80
Date Published2012 Sep
ISSN1536-3732
KeywordsBrachytherapy, Ear, External, Female, Humans, Keloid, Radiotherapy Dosage, Recurrence, Skin Transplantation, Thigh, Young Adult
Abstract

<p>Keloids present a formidable clinical challenge. Surgical excision in conjunction with radiation therapy may decrease the chance of keloid recurrence. Split-thickness skin grafts, however, are more prone to failure in the setting of radiation. In this report, we present a patient with a recurrent auricular keloid who underwent excision and immediate Integra (Integra LifeSciences, Plainsboro, NJ) application, followed by high-dose rate brachytherapy and interval split-thickness skin graft placement. A 23-year-old woman with a history of a recurrent auricular keloid after previous surgical excision, corticosteroid injection, and radiation underwent reexcision of her keloid. Integra was used to cover the resultant exposed auricular perichondrium. The patient then received high-dose rate brachytherapy (1500 cGy) on postoperative days 1 and 2, followed by definitive split-thickness skin graft placement 3 weeks after her initial surgery. The patient recovered from all interventions without complication. There was no evidence of keloid formation 27 months after the interval split-thickness skin graft placement at either the auricular recipient or thigh donor sites. We report the first case of a 2-stage reconstruction of a recurrent auricular keloid (composed of keloid excision and placement of Integra in conjunction with high-dose rate brachytherapy, followed by interval split-thickness skin grafting), resulting in an acceptable cosmetic result without evidence of recurrence at long-term follow-up.</p>

DOI10.1097/SCS.0b013e3182587388
Alternate JournalJ Craniofac Surg
PubMed ID22976675
PubMed Central IDPMC3445295
Grant ListT32 HL083824 / HL / NHLBI NIH HHS / United States
TL1 RR024998 / RR / NCRR NIH HHS / United States
HL083824-05 / HL / NHLBI NIH HHS / United States
TL1RR024998 / RR / NCRR NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065